Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 71 articles: HTML format

Single Articles

July 2025
1. HOU W, Yao Y, Dun D, Xia Y, et al
   Q fever endocarditis and glomerulonephritis.
   Kidney Int. 2025;108:156.
   PubMed    
   
   
   June 2025
2. MASOUD S, Wong K, Pitcher D, Downward L, et al
   Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry.
   Kidney Int. 2025 Jun 27:S0085-2538(25)00491-0. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
3. FLOEGE J, Lafayette R, Barratt J, Schwartz B, et al
   Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy.
   Kidney Int. 2025 Jun 26:S0085-2538(25)00488-0. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
4. CAZA TN, Arivett BA, Hassen SI, Al-Rabadi LF, et al
   Detection and Characterization of NELL1 Autoantibodies in NELL1 Positive Membranous Nephropathy.
   Kidney Int. 2025 Jun 18:S0085-2538(25)00481-8. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
5. LIU P, Liu S, Dalal V, Lane J, et al
   Evaluation of Methodologies in Anti-nephrin Autoantibody Detection.
   Kidney Int. 2025 Jun 7:S0085-2538(25)00430-2. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
6. ZAND L, Russo I, Vargas-Brochero MJ, Nasr SH, et al
   Phospholipase A2receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2receptor on kidney biopsy.
   Kidney Int. 2025 Jun 6:S0085-2538(25)00428-4. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   May 2025
7. KOOIENGA L, Lee EY, Kim SG, Thomas H, et al
   Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy.
   Kidney Int. 2025 May 30:S0085-2538(25)00414-4. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
8. HANNA C, Basiaga ML, Kastl JT, Caza TN, et al
   PCSK6-associated membranous nephropathy in an adolescent with Sjogren disease.
   Kidney Int. 2025;107:940-942.
   PubMed    
   
   
   
9. BELMONT HM
   Lupus nephritis treat to target normalizing anti-dsDNA, C3, and C4 is a bridge too far.
   Kidney Int. 2025;107:937.
   PubMed    
   
   
   
10. BENYAHIA R, Gueye S, Colombat M, Chauveau D, et al
    Glomerular deposits of neuron-derived neurotrophic factor in a case of membranous nephropathy lacking syphilis signature.
    Kidney Int. 2025;107:935-936.
    PubMed    
    
    
    April 2025
11. OSTENDORF L, Rao DA
    ILC1s drive tissue-aggressive macrophages in experimental lupus nephritis.
    Kidney Int. 2025 Apr 28:S0085-2538(25)00262-5. doi: 10.1016/j.kint.2025.
    PubMed    
    
    
    
12. PAWLUCZYK IZ, Bhachu JS, Brown JR, Lacey M, et al
    B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00324-2. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
13. JERKE U, Eulenberg-Gustavus C, Wagner DL, Schreiber A, et al
    CRISPR-Cas9 mediated proteinase 3 autoantigen deletion as a treatment strategy for anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00325-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
14. EGGENHUIZEN PJ, Ng BH, Lo C, Chang J, et al
    Engineered antigen-specific T regulatory cells suppress autoreactivity to the anti-glomerular basement membrane disease antigen.
    Kidney Int. 2025;107:751-756.
    PubMed     Abstract available
    
    
    
15. SHIRAI Y, Miura K, Morimoto K, Yokoo T, et al
    Reevaluating anti-nephrin autoantibodies by ELISA using human embryonic kidney-derived recombinant extracellular domain of human nephrin.
    Kidney Int. 2025;107:757-759.
    PubMed    
    
    
    March 2025
16. ROUSSELLE A, Lodka D, Sonnemann J, Kling L, et al
    Endothelial but not systemic ferroptosis inhibition protects from antineutrophil cytoplasmic antibody-induced crescentic glomerulonephritis.
    Kidney Int. 2025 Mar 21:S0085-2538(25)00250-9. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
17. ODLER B, Riedl R, Geetha D, Szpirt WM, et al
    The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.
    Kidney Int. 2025;107:558-567.
    PubMed     Abstract available
    
    
    
18. SHAH SI, Paudel S, Dalland JC, McPhail EM, et al
    Concurrent AL amyloidosis and fibrillary glomerulonephritis.
    Kidney Int. 2025;107:579.
    PubMed    
    
    
    February 2025
19. HENGEL FE, Dehde S, Yilmaz A, Bayazit AK, et al
    Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00082-1. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    January 2025
20. FLOEGE J, Bernier-Jean A, Barratt J, Rovin B, et al
    Treatment of Patients with IgA Nephropathy: A call for a new paradigm.
    Kidney Int. 2025 Jan 31:S0085-2538(25)00076-6. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
21. PRUNOTTO M, Nachman PH, Gillespie BS, Beck LH Jr, et al
    Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop.
    Kidney Int. 2025 Jan 28:S0085-2538(24)00776-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
22. CANNEY M, Atiquzzaman M, Zheng Y, Induruwage D, et al
    Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases.
    Kidney Int. 2025;107:143-154.
    PubMed     Abstract available
    
    
    December 2024
23. CHENG C, Li B, Li J, Wang Y, et al
    Multi-stain deep learning prediction model of treatment response in lupus nephritis based on renal histopathology.
    Kidney Int. 2024 Dec 27:S0085-2538(24)00923-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
24. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
    Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
    Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    November 2024
25. AL-AUBODAH TA, Piccirillo CA, Trachtman H, Takano T, et al
    The autoimmune architecture of childhood idiopathic nephrotic syndrome.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00804-4. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
26. KASINATH V, Tsokos GC
    PI3Kalpha in the pathogenesis and treatment of lupus nephritis.
    Kidney Int. 2024 Nov 16:S0085-2538(24)00794-4. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
27. DE VRIESE AS, Sethi S, Fervenza FC
    Lupus Nephritis: Redefining the treatment goals.
    Kidney Int. 2024 Nov 7:S0085-2538(24)00781-6. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
28. LARKINS NG, Craig JC
    Using prediction models to improve care and communicate risk: updated modeling for children with IgA nephropathy.
    Kidney Int. 2024;106:790-792.
    PubMed     Abstract available
    
    
    
29. HU P, Xiao H, Alba MA, Atkins HM, et al
    Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli.
    Kidney Int. 2024;106:870-886.
    PubMed     Abstract available
    
    
    
30. CHEUNG CK, Barratt J, Lafayette R, Liew A, et al
    Targeting APRIL in the treatment of glomerular diseases.
    Kidney Int. 2024;106:806-818.
    PubMed     Abstract available
    
    
    October 2024
31. MACHALITZA M, Debiec H, Krumpelmann B, Ferru N, et al
    PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA(2)R1- or NELL1-associated membranous nephropathy.
    Kidney Int. 2024 Oct 24:S0085-2538(24)00725-7. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
32. VODEHNAL S, Mohan C
    Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.
    Kidney Int. 2024 Oct 4:S0085-2538(24)00696-3. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
33. ROSALES IA, Zhou IY, Ay I, Sojoodi M, et al
    Imaging kidney inflammation using an oxidatively activated MRI probe.
    Kidney Int. 2024;106:671-678.
    PubMed     Abstract available
    
    
    
34. HATTORI M
    Anti-nephrin autoantibodies: novel predictors of post-transplant recurrence of focal segmental glomerular sclerosis.
    Kidney Int. 2024;106:570-572.
    PubMed     Abstract available
    
    
    September 2024
35. CHEN Z, Li X, Li C, Cai J, et al
    The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.
    Kidney Int. 2024;106:540.
    PubMed    
    
    
    August 2024
36. SELVASKANDAN H, Barratt J
    The mucosal microbiome and IgA nephropathy: a new target for treatment?
    Kidney Int. 2024 Aug 29:S0085-2538(24)00621-5. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
37. VRANA JA, Theis JD, Wegwerth PJ, Dasari S, et al
    A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry.
    Kidney Int. 2024 Aug 26:S0085-2538(24)00618-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
38. SETHI S, Madden B, Moura MC, Nasr SH, et al
    FAT1 is a target antigen in a subset of de novo allograft membranous nephropathy associated with antibody mediated rejection.
    Kidney Int. 2024 Aug 22:S0085-2538(24)00569-6. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    July 2024
39. BARBOUR SJ, Coppo R, Er L, Russo ML, et al
    Application of the updated International IgA Nephropathy Prediction Tool in children one- or two-years post-biopsy.
    Kidney Int. 2024 Jul 31:S0085-2538(24)00532-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
40. FU R, Wang W, Huo Y, Li L, et al
    The mechanosensitive ion channel Piezo1 contributes to podocyte cytoskeleton remodeling and development of proteinuria in lupus nephritis.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00529-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
41. CHOU YL, Chen HL, Hsu BG, Yang CY, et al
    Galectin-3 contributes to pathogenesis of IgA nephropathy.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00527-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    June 2024
42. TANG J, Xiao Z, Liu L, Li X, et al
    Renal artery microaneurysms in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2024;105:1326.
    PubMed    
    
    
    
43. ROVIRA J, Arana C, Garcia-Busquets A, Gille I, et al
    Chimeric autoantibody receptor cell therapy for the treatment of membranous nephropathy.
    Kidney Int. 2024;105:1320.
    PubMed    
    
    
    
44. HAAS M
    Podocyte injury as a potential therapeutic target in IgA nephropathy: should pathology guide us?
    Kidney Int. 2024;105:1165-1167.
    PubMed     Abstract available
    
    
    
45. UEDA Y, Nakazawa D, Nishio S, Shiratori-Aso S, et al
    Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2024;105:1291-1305.
    PubMed     Abstract available
    
    
    May 2024
46. ABBAD L, Detrait M, Kavvadas P, Bergonnier D, et al
    Signaling through cAMP-Epac1 induces metabolic reprogramming to protect podocytes in glomerulonephritis.
    Kidney Int. 2024 May 29:S0085-2538(24)00380-6. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    April 2024
47. NARAYANAN R, Sivadas S, Kurien AA
    NELL-1 associated membranous nephropathy linked to skin fairness cream use- insights from an Indian case series.
    Kidney Int. 2024 Apr 12:S0085-2538(24)00263-1. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    
48. SELVASKANDAN H, Barratt J
    Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?
    Kidney Int. 2024;105:659-661.
    PubMed     Abstract available
    
    
    March 2024
49. BELLUR SS, Troyanov S, Vorobyeva O, Coppo R, et al
    Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
    Kidney Int. 2024 Mar 28:S0085-2538(24)00235-7. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
50. LAFAYETTE R, Barbour S, Israni R, Wei X, et al
    A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
    Kidney Int. 2024 Mar 27:S0085-2538(24)00236-9. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
51. WANG H, Zuiani J, Coates Ao PT, Xia Y, et al
    Reconstructing the interface between the human intestine and immune system: potential to advance mechanistic studies in IgA nephropathy.
    Kidney Int. 2024;105:423-426.
    PubMed    
    
    
    
52. FLOEGE J, Jayne DRW, Sanders JF, Tesar V, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
    Kidney Int. 2024;105:447-449.
    PubMed     Abstract available
    
    
    
53. 
    KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
    Kidney Int. 2024;105.
    PubMed    
    
    
    February 2024
54. VOINESCU CD, Mozere M, Genovese G, Downie ML, et al
    A Neanderthal haplotype introgressed into the human genome confers protection against membranous nephropathy.
    Kidney Int. 2024 Feb 14:S0085-2538(24)00073-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
55. TANIGUCHI T, Hiwa R, Morinobu A
    Pitfalls in evaluating the impact of persistent hematuria after induction therapy on kidney prognosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Kidney Int. 2024;105:391-392.
    PubMed    
    
    
    
56. WIMBURY D, Muto M, Bhachu JS, Scionti K, et al
    Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.
    Kidney Int. 2024;105:381-388.
    PubMed    
    
    
    
57. SEIFERT L, Riecken K, Zahner G, Hambach J, et al
    An antigen-specific chimeric autoantibody receptor NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.
    Kidney Int. 2024 Feb 1:S0085-2538(24)00080-2. doi: 10.1016/j.kint.2024.
    PubMed    
    
    
    January 2024
58. WANG H, Shen M, Ma Y, Lan L, et al
    Novel mitophagy inducer alleviates lupus nephritis by reducing myeloid cell activation and autoantigen presentation.
    Kidney Int. 2024 Jan 29:S0085-2538(24)00064-4. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
59. ROVIN BH, Ayoub IM, Chan TM, Liu ZH, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
    Kidney Int. 2024;105:31-34.
    PubMed     Abstract available
    
    
    
60. FLOEGE J
    A new alternative: inhibiting complement activation in patients with IgA nephropathy.
    Kidney Int. 2024;105:28-30.
    PubMed     Abstract available
    
    
    
61. 
    KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.
    Kidney Int. 2024;105.
    PubMed    
    
    
    
62. LUCIENTES-CONTINENTE L, Fernandez-Juarez G, Marquez-Tirado B, Jimenez-Villegas L, et al
    Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
    Kidney Int. 2024;105:177-188.
    PubMed     Abstract available
    
    
    
63. DYLEWSKI JF, Haddad G, Blaine J
    Exploiting the neonatal crystallizable fragment receptor to treat kidney disease.
    Kidney Int. 2024;105:54-64.
    PubMed     Abstract available
    
    
    December 2023
64. RIVEDAL M, Mikkelsen H, Marti HP, Liu L, et al
    Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy.
    Kidney Int. 2023 Dec 26:S0085-2538(23)00920-1. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
65. KISTLER AD, Salant DJ
    Complement Activation and Effector Pathways in Membranous Nephropathy.
    Kidney Int. 2023 Dec 21:S0085-2538(23)00868-2. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
66. ROBSON KJ
    Laminin-521: a novel target for pathogenic autoantibodies in anti-glomerular basement membrane disease.
    Kidney Int. 2023;104:1054-1056.
    PubMed     Abstract available
    
    
    November 2023
67. BECK LH JR
    The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy.
    Kidney Int. 2023;104:878-880.
    PubMed     Abstract available
    
    
    October 2023
68. ZHANG H, Rizk DV, Perkovic V, Maes B, et al
    Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
    Kidney Int. 2023 Oct 30:S0085-2538(23)00754-8. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    
    
69. KIM M, Kim SS, Choi HI, Choi HS, et al
    Cryofibrinogen-associated membranoproliferative glomerulonephritis.
    Kidney Int. 2023;104:860.
    PubMed    
    
    
    
70. TANIGUCHI T, Hiwa R, Morinobu A
    The conclusion that myeloperoxidase inhibition is not protective against anti-neutrophil cytoplasmic autoantibody-associated vasculitis is premature.
    Kidney Int. 2023;104:856.
    PubMed    
    
    
    September 2023
71. SETHI S, Beck LH Jr, Glassock RJ, Haas M, et al
    Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.
    Kidney Int. 2023 Sep 6:S0085-2538(23)00490-8. doi: 10.1016/j.kint.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.